- Home
- AII vs PHAT Comparison
AII vs PHAT Comparison
Compare AII & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AII
- PHAT
- Stock Information
- Founded
- AII 2006
- PHAT 2018
- Country
- AII United States
- PHAT United States
- Employees
- AII N/A
- PHAT N/A
- Industry
- AII Property-Casualty Insurers
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- AII Finance
- PHAT Health Care
- Exchange
- AII Nasdaq
- PHAT Nasdaq
- Market Cap
- AII 323.7M
- PHAT 289.0M
- IPO Year
- AII 2025
- PHAT 2019
- Fundamental
- Price
- AII $17.86
- PHAT $9.76
- Analyst Decision
- AII Buy
- PHAT Strong Buy
- Analyst Count
- AII 3
- PHAT 5
- Target Price
- AII $21.50
- PHAT $16.40
- AVG Volume (30 Days)
- AII 174.7K
- PHAT 4.8M
- Earning Date
- AII 01-01-0001
- PHAT 08-07-2025
- Dividend Yield
- AII N/A
- PHAT N/A
- EPS Growth
- AII N/A
- PHAT N/A
- EPS
- AII 3.19
- PHAT N/A
- Revenue
- AII $231,932,000.00
- PHAT $81,859,000.00
- Revenue This Year
- AII $25.17
- PHAT $195.45
- Revenue Next Year
- AII $34.03
- PHAT $106.76
- P/E Ratio
- AII $5.54
- PHAT N/A
- Revenue Growth
- AII 1.73
- PHAT 3055.70
- 52 Week Low
- AII $15.78
- PHAT $2.21
- 52 Week High
- AII $19.45
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- AII N/A
- PHAT 68.64
- Support Level
- AII N/A
- PHAT $8.86
- Resistance Level
- AII N/A
- PHAT $11.21
- Average True Range (ATR)
- AII 0.00
- PHAT 1.57
- MACD
- AII 0.00
- PHAT 0.12
- Stochastic Oscillator
- AII 0.00
- PHAT 67.38
About AII American Integrity Insurance Group Inc. Common Stock
American Integrity Insurance Group Inc is engaged in the property and casualty insurance business. It provides personal residential property insurance for single-family homeowners and condominium owners as well as coverage for vacant dwellings and investment properties, predominantly in Florida. The Company's property and casualty insurance is currently offered in Florida, South Carolina, and Georgia.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.